Telesis Bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
March 21, 2023 at 04:16 pm
Share
Telesis Bio, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was USD 3.46 million compared to USD 0.16 million a year ago. Revenue was USD 9.47 million compared to USD 3.08 million a year ago. Net loss was USD 8.13 million compared to USD 12.49 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.43 a year ago.
For the full year, sales was USD 6.65 million compared to USD 0.16 million a year ago. Revenue was USD 27.44 million compared to USD 11.04 million a year ago. Net loss was USD 48.47 million compared to USD 38.96 million a year ago. Basic loss per share from continuing operations was USD 1.65 compared to USD 2.14 a year ago.
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.
TELESIS BIO, INC. 
